uniQure Shares Drop Additional 12.86% After FDA Rejects Trial Data, Down 56% YTD

Investing.com Gold reports: uniQure Shares Drop Additional 12.86% After FDA Rejects Trial Data, Down 56% YTD. This is a premium/paywalled source, so the brief is based on headline and available metadata only.